Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Diluted Average) (2021 - 2025)

Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $79.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 10.58% year-over-year to $79.0 million; the TTM value through Dec 2025 reached $79.0 million, up 10.58%, while the annual FY2025 figure was $79.0 million, 10.58% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $79.0 million in Q4 2025 per KNSA's latest filing, up from $78.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $79.0 million in Q4 2025 to a low of $68.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $71.6 million, with a median of $70.6 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): decreased 1.14% in 2024, then rose 10.58% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $68.6 million in 2021, then grew by 2.69% to $70.4 million in 2022, then rose by 2.13% to $71.9 million in 2023, then fell by 0.69% to $71.4 million in 2024, then increased by 10.58% to $79.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Shares Outstanding (Diluted Average) are $79.0 million (Q4 2025), $78.0 million (Q3 2025), and $77.9 million (Q2 2025).